Introduction
============

Thiopurines (mercaptopurine, thioguanine, and azathioprine) are commonly used immunosuppressive and anticancer agents. In inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, thiopurines are the first-line regimens in patients with corticosteroid refractory or corticosteroid dependant.[@b1-ott-11-8309]--[@b3-ott-11-8309] Thiopurines are also commonly prescribed for patients with acute lymphoblastic leukemia (ALL), as prolonged daily exposure to mercaptopurine is an important component of contemporary treatment regimens.[@b4-ott-11-8309],[@b5-ott-11-8309] Unfortunately, up to 40% of patients discontinue thiopurine therapy owing to intolerable adverse effects, especially leukopenia, which is the most common and life-threatening toxicity in Asian patients.[@b5-ott-11-8309],[@b6-ott-11-8309] Therefore, predictors that can forecast the risk of leukopenia are strongly needed to accurately and efficiently use thiopurines.

The metabolism of thiopurines is complex and involves several primary active intermediates, such as nucleoside triphosphates, 6-thio-GTP, and 6-thio-dGTP.[@b7-ott-11-8309] Nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) is a 164-amino-acid protein that belongs to the nudix hydrolase enzyme family, which is hypothesized to catalyze the hydrolysis of 6-thio-GTP and 6-thio-dGTP, thus preventing their incorporation into DNA and playing a negative role with respect to the adverse effects of thiopurines.[@b8-ott-11-8309] Studies revealed that the novel gene *NUDT15* R139C variant (rs116855232; C415T; encoding p.Arg139Cys) could decrease thermal stability of NUDT15.[@b9-ott-11-8309] Moreover, in 2014, Yang et al[@b10-ott-11-8309] first reported that the *NUDT15* R139C variant confers susceptibility to thiopurine-induced leukopenia. Since then, there have been numerous publications, mostly in patients of Asian origin, that further supported Yang et al's findings.[@b11-ott-11-8309]--[@b15-ott-11-8309] Furthermore, this variant is most common in East Asians, rare in Europeans, and not observed in Africans. Hence, we aimed to perform a systematic review and meta-analysis to gather and analyze the data regarding the association between *NUDT15* R139C variant and thiopurine-induced leukopenia in Asians.

Materials and methods
=====================

Search strategy
---------------

A literature research was conducted using PubMed, Web of Science, Embase, and Cochrane Library up to May 2018 with English-language restriction. Relevant studies were searched using the terms \[*NUDT15* or rs116855232 or *NUDT15* R139C or NUDT15 c.415C\>T\] AND \[variant or genetic polymorphism or polymorphisms or mutation\]. Additional studies were identified by screening references in the retrieved articles and preceding reviews on the topic.

Inclusion and exclusion criteria
--------------------------------

Studies were included if they met the following criteria: 1) they described the association between *NUDT15* R139C polymorphism and risks of thiopurine-induced leukopenia in Asians; and 2) they reported the genotype frequencies of cases and controls or the data could be calculated from the paper. Accordingly, the exclusion criteria were 1) reviews or letters, or case report; 2) duplicate data; 3) reports only concerned with leukopenia; and 4) studies with sample size \<30.

Date extraction and quality assessment
--------------------------------------

Two of the authors independently selected the articles and extracted data with consensus regarding all search terms. If the data were not identical, both investigators would check the data again to arrive at an agreement. If they could not reach an agreement, an expert (W.D.) would intervene and help make a decision. The following items were collected from the eligible articles: first author's name, year of publication, country of origin, ethnicity, year of publication, type of disease, leukopenia-onset time, number of cases and controls, age of onset, thiopurine regimens, leukopenia criteria, number of early leukopenia cases induced by thiopurines, number of late leukopenia cases induced by thiopurines, and the method of single-nucleotide polymorphism detection.

The quality of the selected studies was independently evaluated on the basis of the Newcastle--Ottawa Scale (NOS).[@b16-ott-11-8309] Studies with six or more stars were considered as high quality.

Statistical analysis
--------------------

Meta-analysis was performed using the Cochrane Collaboration Revman 5.3 (Copenhagen, 2014) and STATA package version 12.0 (StataCorp LP, College Station, TX). The pooled ORs ad 95% CIs were calculated to evaluate the association between the *NUDT15* R139C polymorphism and thiopurine-induced leukopenia risk. In addition, subgroup analyses were performed based on disease type and leukopenia-onset time when adequate data were available. We used the chi-squared-based Q statistic to assess the heterogeneity between the studies.[@b17-ott-11-8309],[@b18-ott-11-8309] When *I*^2^\>50% and *P≤*0.05, the heterogeneity was considered significant, and the random-effects model was used to analyze the data; otherwise, the fixed-effects model was used.[@b19-ott-11-8309] Hardy--Weinberg equilibrium (HWE) among the control subjects was examined with the chi-squared test. We evaluated the association of *NUDT15* R139C polymorphism with susceptibility to thiopurine-induced leukopenia in the dominant, recessive, codominant, and heterozygous models. Then, we calculated the sensitivity to evaluate the stability of the results after eliminating the studies without HWE. Publication bias was diagnosed using Begg's funnel plot[@b20-ott-11-8309] and Egger's linear regression.[@b21-ott-11-8309] *P*\<0.05 was regarded as a state of disequilibrium.

Results
=======

Study characteristics
---------------------

In total, 97 abstracts were identified and assessed from the initial literature search. According to the inclusion and exclusion criteria, 14 studies[@b10-ott-11-8309]--[@b14-ott-11-8309],[@b22-ott-11-8309]--[@b30-ott-11-8309] with full text were eligible for this meta-analysis. [Figure 1](#f1-ott-11-8309){ref-type="fig"} shows the flow chart of included studies. All studies were conducted in Asia and all study participants were Asian. There were 14 eligible studies including 918 cases (leukopenia) and 2,341 controls (without leukopenia) regarding the *NUDT15* R139C variant. Disease type included IBD (Crohn's disease or ulcerative colitis), ALL, autoimmune hepatitis, and various neurological disease, including myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, vasculitis, and others. Leukopenia with onset within 8 weeks was defined as early leukopenia; otherwise, it was defined as late leukopenia.[@b31-ott-11-8309] Blood samples were obtained from enrolled patients and used to determine genetic polymorphisms in all of the included studies. The distribution of genotypes in controls was consistent with HWE for all, except two studies.[@b11-ott-11-8309],[@b12-ott-11-8309] According to the NOS, the quality of all enrolled studies was high. [Table 1](#t1-ott-11-8309){ref-type="table"} showed the characteristics of the included studies.

Quantitative data synthesis
---------------------------

In this meta-analysis, the allelic frequency of *NUDT15* R139C was 11.2% (732/6,518), and there were 28.2% (918/3,259) patients with thiopurine-induced leukopenia. Overall, *NUDT15* R139C polymorphism significantly increased susceptibility to thiopurine-induced leukopenia. This association was observed under all four models: dominant model (OR =9.04, 95% CI 6.05--13.50, *P*\<0.001); recessive model (OR =24.26, 95% CI 11.38--51.71, *P*\<0.0010); CT vs TT model (OR =7.60, 95% CI 4.97--11.61, *P*\<0.001); and CC vs TT model (OR =38.47, 95% CI 17.78--83.24, *P*\<0.001) ([Figure 2](#f2-ott-11-8309){ref-type="fig"}, [Table 2](#t2-ott-11-8309){ref-type="table"}).

In IBD patients, eight studies with 755 cases and 1,881 controls were identified. Overall, a significantly increased risk was found under all four models: dominant model (OR =7.57, 95% CI 5.16--11.12, *P*\<0.001); recessive model (OR =32.06, 95% CI 11.10--92.56, *P*\<0.001); CT vs TT model (OR =6.55, 95% CI 4.42--9.70, *P*\<0.001); and CC vs TT model (OR =51.22, 95% CI 17.44--150.48, *P*\<0.001). Similar results were observed in the subgroup of ALL and other diseases ([Table 2](#t2-ott-11-8309){ref-type="table"}).

For early leukopenia, 10 studies with 227 cases and 2,548 controls were identified. Overall, we found a significantly increased risk under the dominant model (OR =15.53, 95% CI 7.91--30.50, *P*\<0.001). For late leukopenia, 10 studies with 603 cases and 2,172 controls were included. Similar results were obtained in the development of late leukopenia (OR =2.92, 95% CI 2.01--4.24, *P*\<0.001) ([Figure 2](#f2-ott-11-8309){ref-type="fig"}).

Test of heterogeneity
---------------------

There was significant heterogeneity for overall comparisons in the dominant (CT + TT vs TT: *P*=0.0002) and heterozygote model (CT vs CC: *P*=0.0001), but not in the recessive (TT vs CC + CT: *P*=0.90) and homozygote comparisons (TT vs CC: *P*=0.78). In the subgroup analysis by disease type, results were similar in IBD, ALL, and other diseases subgroup. For early and late leukopenia, there was significant heterogeneity (*P*~early~ =0.002, *P*~late~ =0.03) ([Table 2](#t2-ott-11-8309){ref-type="table"}).

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to address potential publication bias in the available literature. The shape of funnel plots did not indicate any evidence of funnel plot asymmetry ([Figure 3](#f3-ott-11-8309){ref-type="fig"}). Egger's test also revealed that there was no statistical significance of evaluation of publication bias under the dominant model (415C\>T: *P*=0.497, early leukopenia: *P*=0.245, late leukopenia: *P*=0.952).

Discussion
==========

As prodrugs, thiopurines undergo a series of enzymatic reactions that results in several active species, consisting of 6-thioguanine-monophosphate (6-TGMP), 6-thioguanine-diphosphate (6-TGDP), and 6-thioguanine-triphosphate (6-TGTP).[@b32-ott-11-8309] 6-TGTP is further reduced to 6-deoxythioguanosine-triphosphate (6-TdGTP). Then, 6-TGTP and 6-TdGTP are incorporated into the RNA or DNA to trigger a futile mismatch repair and, eventually, apoptosis.[@b33-ott-11-8309],[@b34-ott-11-8309] Studies from comprehensive in vitro and vivo studies strongly indicated that NUDT15 could hydrolyze 6-TdGTP and 6-TGTP and then prevent the incorporation of these thiopurine metabolites into DNA (DNA-TG), thereby acting as a barrier to the efficacy of thiopurines in cells, and consequently, cytotoxicity.[@b8-ott-11-8309],[@b9-ott-11-8309],[@b35-ott-11-8309],[@b36-ott-11-8309] Moreover, the R139C mutation of *NUDT15* can decrease the thermal stability of NUDT15 that results in NUDT15 degradation[@b9-ott-11-8309] and on average, only about 10% of thiopurine dose routinely tolerated is by patients with wild-type alleles.[@b8-ott-11-8309]

Routine examination of (thiopurine methyltransferase) *TPMT* genotype status prior to initiation of thiopurine therapy has been recommended in several clinical practice guidelines to reduce the risks of myelosuppression.[@b37-ott-11-8309],[@b38-ott-11-8309] However, series studies have confirmed that in Asian patients the variations in *TPMT* gene were rare and might not be clinically relevant in predicting toxicity.[@b15-ott-11-8309],[@b39-ott-11-8309],[@b40-ott-11-8309] *NUDT15* c.415C\>T is a missense variant in the *NUDT15* gene (rs116855232, encoding p.Arg139Cys) and the allele frequency of the mutation is \~10%--20% in the Asian population.[@b10-ott-11-8309],[@b22-ott-11-8309],[@b41-ott-11-8309] By contrast, it is much lower in Caucasians with an occurrence of only 0.4%. Recently, researchers have reported that the *NUDT15* R139C variant is strongly associated with thiopurine-related myelosuppression in patients with IBD[@b10-ott-11-8309],[@b25-ott-11-8309] and in children with ALL.[@b29-ott-11-8309],[@b42-ott-11-8309] Studies reported that *NUDT15* c.415C\>T may be a better predictor for thiopurine-reduced leukopenia than *TPMT* polymorphism in the Asian population.

The current meta-analysis found that the allele frequency of NUDT15 c.415C\>T was 11.2% (732/6518) and the risk of developing leukopenia was significantly increased by 3.02-fold compared with patients without the T-allele mutation, which was similar to the range observed on other studies in East Asians.[@b27-ott-11-8309],[@b29-ott-11-8309] We calculated that the *NUDT15* c.415C\>T allele was strongly associated with an increased risk of developing thiopurine-related leukopenia and this result was confirmed among studies with HWE. In the subgroup of IBD, ALL, and other diseases, similar results were observed. Among these, thiopurine-induced leukopenia among Asian populations have been robustly linked to the *NUDT15* R139C genetic variant. Therefore, the utility of routine genotyping for the *NUDT15* R139C variant before initiating thiopurine therapy should be considered to reduce the risk of thiopurine-related leukopenia.

Meanwhile, there have been different observations in recent studies of the *NUDT15* R139C variant in East Asians. Yang et al showed that *NUDT15* R139C was associated with both early and late leukopenia in the Korean population.[@b10-ott-11-8309] In addition, Asada et al found that a decrease in the white blood cell count was rapidly induced (within 2 weeks) after thiopurine initiation in patients carrying *NUDT15* R139C. However, Kakuta et al[@b13-ott-11-8309] reported that the presence of *NUDT15* R139C was associated with only early leukopenia, but not late leukopenia, in the Japanese population. This meta-analysis showed that the Asian population *NUDT15* R139C was significantly associated with the development of late leukopenia (OR =2.92, 95% CI 2.01--4.24) and a much stronger association with early leukopenia (OR =15.53, 95% CI 7.91--30.50). We also found that more patients develop late leukopenia (21.7%, 603/2,775) than early leukopenia (8.2%, 227/2,775). Several studies[@b22-ott-11-8309],[@b41-ott-11-8309] also found that patients with T mutation were more likely to develop severe leukopenia. The reason for the discrepancy might be owing to different azathiopurine dosage and different diagnostic criteria of leukopenia. Further studies are necessary to clarify this association.

Some of the highlights of our meta-analysis should be noted. First, this research sheds light on the relationship between the *NUDT15* R139C genetic polymorphism and the increased susceptibility to thiopurine-induced leukopenia in the Asian population. Second, the exhaustive inclusion criteria and articles on different types of disease enhanced the power and validity of our conclusion. Furthermore, all literature included had acceptable quality scores (scored at least 6). We also acknowledge that our study has some limitations. First, we only investigated the *NUDT15* p.Arg139Cys mutation, but not other coding variants of *NUDT15*, such as *NUDT15* p.Val18_Val19insGlyVal and p.Val18Ile. Second, the search terms were chosen only from the genetic aspect, and did not include leukopenia and toxicity to thiopurines. Third, the number of the studies, especially for ALL patients, was not sufficiently large.

Conclusion
==========

In summary, we verified the strong association between *NUDT15* c.415C\>T polymorphism and thiopurine-induced leukopenia (both early and late leukopenia) in an Asian population with IBD, ALL, and other diseases. Thus, NUDT15 c.415C\>T genotyping should currently be prioritized for the prediction of leukopenia among the Asian population, and its application in precision medicine should be considered in the future. Further research is necessary to verify this relationship and determine the precise mechanism.
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###### 

Meta-analysis of the association between *NUDT15* c.415C.T polymorphism and susceptibility to thiopurine-induced leukopenia under dominant model.

**Notes:** (**A**) All leukopenia. (**B**) Early leukopenia. (**C**) Late leukopenia.

**Abbreviations:** ALL, acute lymphoblastic leukemia; IBD, inflammatory bowel disease.
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![Begg's funnel plot for publication bias under dominant model.\
**Notes:** (**A**) All leukopenia. (**B**) Early leukopenia. (**C**) Late leukopenia.](ott-11-8309Fig3){#f3-ott-11-8309}

###### 

Characteristics of studies included in the meta-analysis

  Study                                 Year   Ethnicity   Diseases                Number    Leukopenia diagnostic criteria     Genotype (case/control)   P~HWE~   NOS            
  ------------------------------------- ------ ----------- ----------------------- --------- ---------------------------------- ------------------------- -------- ------ ------- ---
  Asada et al[@b22-ott-11-8309]         2016   Japanese    IBD                     45/116    WBC \<3,000/μL                     25/102                    18/14    2/0    0.489   9
  Chao et al[@b11-ott-11-8309]          2017   Chinese     IBD                     177/555   WBC \<3,500/μL                     90/467                    76/88    11/0   0.043   9
  Kakuta et al[@b13-ott-11-8309]        2016   Japanese    IBD                     34/101    WBC \<3,000/μL                     19/88                     10/13    5/0    0.489   9
  Sato et al[@b23-ott-11-8309]          2017   Japanese    IBD                     59/90     WBC \<3,000/μL                     29/80                     24/9     6/1    0.223   8
  Sutiman et al[@b25-ott-11-8309]       2018   Asian       IBD                     10/119    WBC \<3,000/μL                     3/108                     5/11     2/0    0.597   8
  Wang et al[@b27-ott-11-8309]          2018   Chinese     IBD                     19/80     WBC \<3,000/μL or ANC \<1,500/μL   11/64                     8/16     0/0    0.320   8
  Yang et al[@b10-ott-11-8309]          2014   Korean      IBD                     346/632   WBC \<3,000/μL                     199/589                   133/43   14/0   0.376   7
  Zhu et al[@b29-ott-11-8309]           2016   Chinese     IBD                     65/188    WBC \<3,500/μL                     25/171                    36/17    4/0    0.516   6
  Chiengthong et al[@b12-ott-11-8309]   2016   Thai        ALL                     28/54     ANC \<500/μL                       18/52                     9/1      1/1    0.000   6
  Tanaka et al[@b26-ott-11-8309]        2018   Japanese    ALL                     38/57     WBC \<2,000/μL or ANC \<1,000/μL   19/51                     13/5     6/1    0.071   9
  Zhou et al[@b28-ott-11-8309]          2018   Chinese     ALL                     23/82     WBC \<2,000/μL                     11/63                     10/19    2/0    0.235   9
  Zhu et al[@b30-ott-11-8309]           2018   Chinese     ALL                     48/140    WBC \<2,000/μL                     15/136                    27/4     6/0    0.864   6
  Kim et al[@b14-ott-11-8309]           2017   Korean      Neurological diseases   20/64     WBC \<3,500/μL                     12/59                     3/5      5/0    0.745   7
  Shah et al[@b24-ott-11-8309]          2017   Indian      IBD + AIH               6/63      WBC \<3,000/μL                     0/60                      5/3      1/0    0.846   9

**Notes:** P~HWE~ was calculated by goodness-of fit chi-squared test, P~HWE~ \<0.05 was considered statistically significant.

**Abbreviations:** AIH, autoimmune hepatitis; ALL, acute lymphoblastic leukemia; Ht, heterozygote; HWE, Hardy--Weinberg equilibrium; IBD, inflammatory bowel disease; NOS, Newcastle--Ottawa Scale; VR Ho, variant homozygote; WBC, white blood cell; WT Ho, wild-type homozygote.

###### 

Summary of ORs of the *NUDT15* R139C polymorphism and thiopurine-induced leukopenia

  Disease             n    Dominant model                                                    Recessive model   Ht vs WT Ho                                                       VR Ho vs WT Ho                                                                                                       
  ------------------- ---- ----------------------------------------------------------------- ----------------- ----------------------------------------------------------------- ---------------- ----------------------- -------- ------------------------------------------------------------------ ------
  Total                                                                                                                                                                                                                                                                                               
   All studies        14   9.04 (6.05--13.50)                                                0.0002            24.26 (11.38--51.71)[b](#tfn4-ott-11-8309){ref-type="table-fn"}   0.90             7.60 (4.97--11.61)      0.0001   38.47 (17.78--83.24)[b](#tfn4-ott-11-8309){ref-type="table-fn"}    0.78
   Studies with HWE   12   9.60 (6.09--15.12)                                                0.0009            25.13 (10.71--58.99)[b](#tfn4-ott-11-8309){ref-type="table-fn"}   0.99             7.85 (4.87--12.65)      0.0008   40.79 (17.00--97.86)[b](#tfn4-ott-11-8309){ref-type="table-fn"}    0.94
   IBD                8    7.57 (5.16--11.12)                                                0.02              32.06 (11.10--92.56)[b](#tfn4-ott-11-8309){ref-type="table-fn"}   0.90             6.55 (4.42--9.70)       0.02     51.22 (17.44--150.48)[b](#tfn4-ott-11-8309){ref-type="table-fn"}   0.89
   ALL                4    13.13 (3.43--50.23)                                               0.001             12.43 (3.62--42.69)[b](#tfn4-ott-11-8309){ref-type="table-fn"}    0.48             12.62 (2.91--54.78)     0.001    19.88 (5.82--67.94)[b](#tfn4-ott-11-8309){ref-type="table-fn"}     0.35
   Others             2    31.22 (1.20--814.07)[b](#tfn4-ott-11-8309){ref-type="table-fn"}   0.05              42.43 (4.23--425.17)[b](#tfn4-ott-11-8309){ref-type="table-fn"}   0.89             19.07 (0.31--1160.45)   0.007    67.02 (4.62--972.29)[b](#tfn4-ott-11-8309){ref-type="table-fn"}    0.43

**Notes:**

Test for heterogeneity.

Fixed-effect model was used when the *P* for heterogeneity test was ≥0.05, otherwise the random-effect model was used.

**Abbreviations:** ALL, acute lymphoblastic leukemia; IBD, inflammatory bowel disease; n, number of studies; Ht + VR Ho vs WT Ho, dominant model; HWE, Hardy--Weinberg equilibrium; VR Ho, variant homozygote; SNP, single-nucleotide polymorphism; vs Ht + WT Ho, recessive model.
